WestGene
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese biotech developing cutting-edge cell and gene therapies targeting various cancers.
Oncology
Technology Platform
A proprietary platform for engineering chimeric antigen receptor (CAR) T-cells and other immune effector cells for cancer therapy.
Opportunities
Potential to capture significant market share in China's large oncology market with a successful approved therapy.
Risk Factors
High clinical development risk and intense competition could limit commercial success for any single product.
Competitive Landscape
Operates in the highly competitive Chinese CAR-T arena, competing on clinical data, manufacturing cost, and novel target selection.